Search results for " sodium"

showing 10 items of 196 documents

The Effect of Dopants on Sintering and Microstructure of Lead-free KNN Ceramics

2011

Lead-free potassium sodium niobate (K0.5Na0.5)NbO3 (KNN) has been prepared via conventional ceramic processing method. The influence of 0.5 wt% - 1.5 wt% MnO2 and WO3 addition on the sintering, crystallographic structure, microstructure and dielectric properties of KNN has been investigated. Optimal sintering temperatures of KNN ceramics were observed to be in the narrow interval: 1090 °C - 1110 °C for MnO2 doped KNN; 1150 °C - 1170 °C for pure KNN and doped with WO3. XRD patterns showed that all the samples have single perovskite structure with monoclinic structure. Microstructure of ceramics was changed greatly by using dopants.http://dx.doi.org/10.5755/j01.ms.17.1.251

lead-freelcsh:TN1-997sinteringMaterials scienceDopantDopingAnalytical chemistrySinteringMineralogyDielectricCrystal structureMicrostructurepotassium sodium niobatevisual_artpiezoelectric ceramicsvisual_art.visual_art_mediumoxide additivesGeneral Materials ScienceCeramiclcsh:Mining engineering. MetallurgyMonoclinic crystal systemMedžiagotyra
researchProduct

Glycerosomes:investigation of role of 1,2-dimyristoyl-sn-glycero-3-phosphatidycholine (DMPC) on the assembling and skin delivery performances

2017

Glycerosomes were formulated using 1,2-dimyristoyl-sn-glycero-3-phosphatidycholine (DMPC), diclofenac sodium salt and 10, 20 or 30% glycerol in the water phase, while corresponding liposomes were prepared with the same amount of DMPC and diclofenac, without glycerol. The aim of the present work was to evaluate the effect of the used phospholipid on vesicle features and ability to favour diclofenac skin deposition by comparing these results with those found in previous works performed using hydrogenated soy phosphatidylcholine (P90H) and dipalmitoylphosphatidylcholine (DPPC). Liposomes and glycerosomes were multilamellar, liposomes being smaller (72±6nm). Interactions among glycerol, phospho…

liposomes3003skindimyristoylphosphatidylcholinePhospholipidPharmaceutical Science02 engineering and technologyrehological studies010402 general chemistry01 natural sciencesDSCchemistry.chemical_compoundglycerosomesdrug delivery systemsPhosphatidylcholineGlycerolskin deliveryDSC; glycerosomes; rehological studies; SAXS; skin delivery; animals; diclofenac; dimyristoylphosphatidylcholine; liposomes; skin; swine; drug delivery systems; skin absorption; 3003LiposomeChromatographyBilayerVesicletechnology industry and agricultureswineDiclofenac SodiumSAXS021001 nanoscience & nanotechnologyskin absorption0104 chemical sciencesanimalsdiclofenacchemistryDipalmitoylphosphatidylcholinelipids (amino acids peptides and proteins)0210 nano-technology
researchProduct

Effect of Stacking Sequence and Sodium Bicarbonate Treatment on Quasi-Static and Dynamic Mechanical Properties of Flax/Jute Epoxy-Based Composites

2019

The present paper deals with the investigation of quasi-static and dynamic mechanical response of epoxy-based composites reinforced with flax and/or jute plain weave fabrics. In order to evaluate the influence of the stacking sequence, two monolithic laminates reinforced with flax or jute fibers and two hybrid flax/jute laminates were manufactured through the vacuum infusion technique. Furthermore, an eco-friendly and cost-effective surface treatment based on fiber soaking in a sodium bicarbonate solution was employed to improve the fiber-matrix adhesion. The mechanical characterization (by means of quasi-static flexural, dynamic mechanical thermal analysis and Charpy impact tests) allowed …

mechanical characterizationMaterials scienceGreen composites; Hybridization; Mechanical characterization; Sodium bicarbonate treatmentStackingCharpy impact test02 engineering and technologylcsh:TechnologyArticlechemistry.chemical_compound0203 mechanical engineeringFlexural strengthGeneral Materials ScienceFiberComposite materialThermal analysislcsh:Microscopyhybridizationsodium bicarbonate treatmentlcsh:QC120-168.85Sodium bicarbonatelcsh:QH201-278.5green compositeslcsh:TEpoxy021001 nanoscience & nanotechnologySettore ING-IND/22 - Scienza E Tecnologia Dei Materiali020303 mechanical engineering & transportschemistrylcsh:TA1-2040visual_artvisual_art.visual_art_mediumPlain weavelcsh:Descriptive and experimental mechanicslcsh:Electrical engineering. Electronics. Nuclear engineeringGreen composite0210 nano-technologylcsh:Engineering (General). Civil engineering (General)lcsh:TK1-9971Materials
researchProduct

Rationale and Design of the Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure Study

2021

AIMS: Although acute heart failure (AHF) with volume overload is treated with loop diuretics, their dosing and type of administration are mainly based upon expert opinion. A recent position paper from the Heart Failure Association (HFA) proposed a step-wise pharmacologic diuretic strategy to increase the diuretic response and to achieve rapid decongestion. However, no study has evaluated this protocol prospectively. METHODS AND RESULTS: The Efficacy of a Standardized Diuretic Protocol in Acute Heart Failure (ENACT-HF) study is an international, multicentre, non-randomized, open-label, pragmatic study in AHF patients on chronic loop diuretic therapy, admitted to the hospital for intravenous …

medicine.drug_classmedicine.medical_treatmentStudy DesignsDecongestionVolume overloadDiuresisNatriuresisSodium Potassium Chloride Symporter InhibitorsFurosemideAcute heart failure; Diuretics; Urinary sodium; Decongestion; ProtocolmedicineClinical endpointProtocolHumansDiseases of the circulatory (Cardiovascular) systemInfusions IntravenousDiureticsHeart FailureUrinary sodiumStudy Designbusiness.industryFurosemideAcute heart failureLoop diureticmedicine.diseaseAnesthesiaHeart failureRC666-701DiureticCardiology and Cardiovascular Medicinebusinessmedicine.drugESC Heart Failure
researchProduct

Impact of switching from mycophenolate mofetil to enteric-coated mycophenolate sodium on gastrointestinal side effects in patients with autoimmune di…

2015

Bernhard Manger,1 Falk Hiepe,2 Matthias Schneider,3 Margitta Worm,4 Peter Wimmer,5 Eva-Maria Paulus,5 Andreas Schwarting6 1University Hospital Erlangen, Med Clinic III Polyclinic, Erlangen, 2Rheumatology, University Hospital Charité, Campus Mitte, Berlin, 3Policlinic of Rheumatology, Heinrich-Heine-Universität, Düsseldorf, 4Department of Dermatology, Venereology and Allergology, University Hospital Charité, Campus Mitte, Berlin, 5Novartis Pharma GmbH, Nürnberg, 6Department of Internal Medicine, Johannes Gutenberg University, Mainz, Germany Background: The purpose of this study was to assess changes in gastrointestinal symptom severity in pati…

medicine.medical_specialtyAbdominal painClinical and Experimental GastroenterologyNauseabusiness.industrymycophenolate mofetilGastroenterologyautoimmune diseaseenteric-coated mycophenolate sodiumpatient-reported outcomeIndigestionhealth-related quality of lifeQuality of lifeRating scaleInternal medicineClinical endpointmedicinePatient-reported outcomemedicine.symptomAdverse effectbusinessOriginal ResearchClinical and Experimental Gastroenterology
researchProduct

Chloride/sodium ratio and sodium.chloride difference inpatients with renal failure and metabolic acidosis in hemodialysis treatment

2018

medicine.medical_specialtyChloride sodiumbusiness.industrySodiummedicine.medical_treatmentClinical Biochemistrychemistry.chemical_elementMetabolic acidosismedicine.diseaseBiochemistryInorganic ChemistryEndocrinologychemistryInternal medicinemedicinemetabolic acidosis chloirde/sodium ratio sodium-chloride difference Stewart's methodIn patientHemodialysisbusiness
researchProduct

Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review

2021

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The latter is a pandemic that has the potential of developing into a severe illness manifesting as systemic inflammatory response syndrome, acute respiratory distress syndrome, multi-organ involvement and shock. In addition, advanced age and male sex and certain underlying health conditions, like type 2 diabetes mellitus (T2DM), predispose to a higher risk of greater COVID-19 severity and mortality. This calls for an urgent identification of antidiabetic agents associated with more favourable COVID-19 outcomes among patients with T2DM, as well as recognition of their potential underlying…

medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)1 receptor agonists Sodium-glucose co-transporter&nbspEndocrinology Diabetes and MetabolismSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)COVID-19 Dipeptidyl peptidase&nbspReviewType 2 diabetesSodium-glucose co-transporter 2 inhibitorsType 2 diabetesGlucagon-like peptide 1 receptor agonistsDiabetes mellitusPandemicInternal Medicinemedicine2 diabetesIntensive care medicineAntidiabetic agents4 inhibitors Glucagon-like peptide&nbspbusiness.industryCOVID-19medicine.diseaseSystemic inflammatory response syndromeShock (circulatory)Dipeptidyl peptidase 4 inhibitorsmedicine.symptombusiness2 inhibitors Type&nbspDiabetes Therapy
researchProduct

Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis

2019

Objective We aimed to assess the safety of topical non-steroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis (OA) in a systematic review and meta-analysis of randomized, placebo-controlled trials. Methods A comprehensive literature search was undertaken in the MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), and Scopus electronic databases. Randomized, double-blind, placebo-controlled, parallel-group trials that assessed adverse events (AEs) with topical NSAIDs in patients with OA were eligible for inclusion. Authors and/or study sponsors were contacted to obtain the full report of AEs. The primary outcomes were overall severe and serious AEs, as w…

medicine.medical_specialtyDICLOFENAC SODIUM GELDiclofenacDrug-Related Side Effects and Adverse ReactionsMedDRAVEHICLE TDT 064MEDLINEOsteoarthritisKNEE OSTEOARTHRITISAdministration CutaneousPlaceboLONG-TERM USE03 medical and health sciencesDOUBLE-BLIND0302 clinical medicinePharmacotherapyInternal medicineOsteoarthritisHumansMedicinePharmacology (medical)030212 general & internal medicineAdverse effectRandomized Controlled Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-SteroidalTRANSFERSOME GELOdds ratiomedicine.diseaseEFFICACYRANDOMIZED CLINICAL-TRIALORAL CELECOXIBTreatment OutcomeMeta-analysisSystematic ReviewGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryTASK-FORCE
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation.

2000

Background —Angiotensin II (Ang II) plays a critical role in the development of vascular lesions in hypertension, atherosclerosis, and several renal diseases. Because Ang II may contribute to the leukocyte recruitment associated with these pathological states, the aim of the present study was to assess the role of Ang II in leukocyte–endothelial cell interactions in vivo. Methods and Results —Intravital microscopy of the rat mesenteric postcapillary venules was used. Sixty minutes of superfusion with 1 nmol/L Ang II induced a significant increase in leukocyte rolling flux (83.8±20.7 versus 16.4±3.1 cells/min), adhesion (11.4±1.0 versus 0.8±0.5 cells/100 μm), and emigration (4.0±0.7 versus …

medicine.medical_specialtyEndotheliumPyridinesLeukocyte RollingCell CommunicationReceptor Angiotensin Type 2LosartanReceptor Angiotensin Type 1Rats Sprague-DawleyDownregulation and upregulationPhysiology (medical)Internal medicineCromolyn SodiummedicineLeukocytesAnimalsEndotheliumReceptorAngiotensin II receptor type 1Receptors Angiotensinbusiness.industryAngiotensin IIImidazolesFlow CytometryAngiotensin IIRatsUp-RegulationEndothelial stem cellP-Selectinmedicine.anatomical_structureEndocrinologyLosartanCardiology and Cardiovascular Medicinebusinessmedicine.drugCirculation
researchProduct